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Abstract
Recent large cancer studies have measured somatic alterations in an unprecedented
number of tumours. These large datasets allow the identification of cancer-related sets of
genetic alterations by identifying relevant combinatorial patterns. Among such patterns,
mutual exclusivity has been employed by several recent methods that have shown its
effectiveness in characterizing gene sets associated to cancer. Mutual exclusivity arises
because of the complementarity, at the functional level, of alterations in genes which are
part of a group (e.g., a pathway) performing a given function. The availability of quantita-
tive target profiles, from genetic perturbations or from clinical phenotypes, provides addi-
tional information that can be leveraged to improve the identification of cancer related
gene sets by discovering groups with complementary functional associations with such
targets. In this work we study the problem of finding groups of mutually exclusive alter-
ations associated with a quantitative (functional) target. We propose a combinatorial
formulation for the problem, and prove that the associated computational problem is com-
putationally hard. We design two algorithms to solve the problem and implement them in
our tool UNCOVER. We provide analytic evidence of the effectiveness of UNCOVER in
finding high-quality solutions and show experimentally that UNCOVER finds sets of alter-
ations significantly associated with functional targets in a variety of scenarios. In particular,
we show that our algorithms find sets which are better than the ones obtained by the state-
of-the-art method, even when sets are evaluated using the statistical score employed by
the latter. In addition, our algorithms are much faster than the state-of-the-art, allowing the
analysis of large datasets of thousands of target profiles from cancer cell lines. We show
that on two such datasets, one from project Achilles and one from the Genomics of Drug
Sensitivity in Cancer project, UNCOVER identifies several significant gene sets with com-
plementary functional associations with targets. Software available at: https://github.com/
VandinLab/UNCOVER.
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Author summary
Sequencing technologies allow the measurement of somatic alterations in a large number
of cancer samples. Several methods have been designed to analyze these alterations, but
the characterization of the functional effects of such alterations is still challenging. A
recent promising approach for such characterization is to combine alteration data with
quantitative profiles obtained, e.g., from genetic perturbations. The analysis of these data
is complicated by the extreme heterogeneity of alterations in cancer, with different cancer
samples exhibiting vastly different alterations. This heterogeneity is due, in part, to the
complementarity of alterations in cancer pathways, with alterations in different genes
resulting in the same alteration at the functional level. We develop UNCOVER, an effi-
cient method to identify sets of alterations displaying complementary functional associa-
tion with a quantitative profile. UNCOVER is much more efficient than the state-of-the-
art, allowing the identification of complementary cancer related alterations from genome-
scale measurements of somatic mutations and genetic perturbations.
Introduction
Recent advances in sequencing technologies now allow to collect genome-wide measurements
in large cohorts of cancer patients (e.g., [1–6]). In particular, they allow the measurement of
the entire complement of somatic (i.e., appearing during the lifetime of an individual) alter-
ations in all samples from large tumour cohorts. The study of such alterations has lead to an
unprecedented improvement in our understanding of how tumours arise and progress [7].
One of the main remaining challenges is the interpretation of such alterations, in particular
identifying alterations with functional impact or with relevance to therapy [8].
Several computational and statistical methods have been recently designed to identify driver
alterations, associated to the disease, and to distinguish them from random, passenger alter-
ations not related with the disease [9]. The identification of genes associated with cancer is
complicated by the extensive intertumour heterogeneity [10], with large (100-1000’s) and dif-
ferent collections of alterations being present in tumours from different patients and no two
tumours having the same collection of alterations [10, 11]. Two main reasons for such hetero-
geneity are that i) most mutations are passenger, random mutations, and, more importantly,
ii) driver alterations target cancer pathways, groups of interacting genes that perform given
functions in the cell and whose alteration is required to develop the disease. Several methods
have been designed to identify cancer genes using a-priori defined pathways [12] or interaction
information in the form of large interaction networks [13, 14].
Recently several methods (see Section Related work) for the de novo discovery of mutated
cancer pathways have leveraged the mutual exclusivity of alterations in cancer pathways.
Mutual exclusivity of alterations, with sets of genes displaying at most one alteration for each
patient, has been observed in various cancer types [7, 11, 15, 16]. The mutual exclusivity prop-
erty is due to the complementarity of genes in the same pathway, with alterations in different
members of a pathway resulting in a similar impact at the functional level, while mutations in
different members of the same pathway may not provide further selective advantage or may
even lead to a disadvantage for the cell (e.g., in synthetic lethality). Even if mutual exclusivity
of alterations is neither a sufficient nor a necessary property of cancer pathways, it has been
successfully used to identify cancer pathways in large cancer cohorts [15, 17, 18].
An additional source of information that can be used to identify genes with complementary
functions are quantitative measures for each samples such as: functional profiles, obtained for
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example by genomic or chemical perturbations [19–21]; clinical data describing, obtained for
example by (quantitative) indicators of response to therapy; activation measurements for
genes or sets of genes, as obtained for example by single sample scores of Gene Set Enrichment
Analysis [22, 23]. The employment of such quantitative measurements is crucial to identify
meaningful complementary alterations since one can expect mutual exclusivity to reflect in
functional properties (of altered samples) that are specific to the altered samples. For example,
consider a scenario (Fig 1) in which there are two altered molecular mechanisms: one that is
altered in almost all samples and one that is altered in much fewer samples, but is related to
the response to a given therapy (for example by interacting with a drug target). Methods that
ignore therapy response information will report the first mechanism as significantly altered,
while the second mechanisms, altered in a smaller fraction of all samples, is identified only by
considering the therapy response information.
Related work
Several recent methods have used mutual exclusivity signals to identify sets of genes important
for cancer [24]. RME [25] identifies mutually exclusive sets using a score derived from infor-
mation theory. Dendrix [26] defines a combinatorial gene set score and uses a Markov Chain
Monte Carlo (MCMC) approach for identifying mutually exclusive gene sets altered in a large
fraction of the patients. Multi-Dendrix [27] extends the score of Dendrix to multiple sets and
uses an integer linear program (ILP) based algorithm to simultaneously find multiple sets with
mutually exclusive alterations. CoMET [18] uses a generalization of Fisher exact test to higher
dimensional contingency tables to define a score to characterize mutually exclusive gene sets
altered in relatively low fractions of the samples. WExT [18] generalizes the test from CoMET
Fig 1. Identification of mutually exclusive alterations associated with a target profile. Alterations in the green set have high
mutual exclusivity but no association with the target profile (e.g., a molecular mechanism commonly altered in cancer). Alterations
in the orange set have lower mutual exclusivity but strong association with the target profile (e.g., genes in the same pathway of the
drug target). Methods that find mutually exclusive sets of alterations without considering the target profile will identify the green set
as the most important gene set.
https://doi.org/10.1371/journal.pcbi.1006802.g001
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to incorporate individual gene weights (probabilities) for each alteration in each sample.
WeSME [28] introduces a test that incorporates the alteration rates of patients and genes and
uses a fast permutation approach to assess the statistical significance of the sets. TiMEx [29]
assumes a generative model for alterations and defines a test to assess the null hypothesis that
mutual exclusivity of a gene set is due to the interplay between waiting times to alterations
and the time at which the tumor is sequenced. MEMo [17] and the method from [30] employ
mutual exclusivity to find gene sets, but use an interaction network to limit the candidate gene
sets. The method by [31] and PathTIMEx [32] introduce an additional dimension to the char-
acterization of inter-tumor heterogeneity, by reconstructing the order in which mutually
exclusive gene sets are mutated. None of these methods take quantitative targets into account
in the discovery of significant gene sets and sets showing high mutual exclusivity may not be
associated with target profiles (Fig 1).
[33] recently developed the repeated evaluation of variables conditional entropy and redun-
dancy (REVEALER) method, to identify mutually exclusive sets of alterations associated with
functional phenotypes. REVEALER uses as objective function (to score a set of alterations) a re-
scaled mutual information metric called information coefficient (IC). REVEALER employs a
greedy strategy, computing at each iteration the conditional mutual information (CIC) of the tar-
get profile and each feature, conditioned on the current solution. REVEALER can be used to find
sets of mutually exclusive alterations starting either from a user-defined seed for the solution or
from scratch, and [33] shows that REVEALER finds sets of meaningful cancer-related alterations.
Our contribution
In this paper we study the problem of finding sets of alterations with complementary func-
tional associations using alteration data and a quantitative (functional) target measure from a
collection of cancer samples. Our contributions in this regard are fivefold. First, we provide a
rigorous combinatorial formulation for the problem of finding groups of mutually exclusive
alterations associated with a quantitative target and prove that the associated computational
problem is NP-hard. Second, we develop two efficient algorithms, a greedy algorithm and an
ILP-based algorithm to identify the set of k genes with the highest association with a target;
our algorithms are implemented in our method fUNctional Complementarity of alteratiOns
discoVERy (UNCOVER). Third, we show that our algorithms identify highly significant sets
of genes in various scenarios; in particular, we compare UNCOVER with REVEALER on the
same datasets used in [33], showing that UNCOVER identifies solutions of higher quality than
REVEALER while being on average two order of magnitudes faster than REVEALER. Interest-
ingly, the solutions obtained by UNCOVER are better than the ones obtained by REVEALER
even when evaluated using the objective function (IC score) optimized by REVEALER. Fourth,
we show that the efficiency of UNCOVER enables the analysis of large datasets, and we analyze
a large dataset from Project Achilles, with thousands of genetic dependencies measurements
and tens of thousands of alterations, and a large dataset from the Genomics of Drug Sensitivity
in Cancer (GDSC) project, with hundreds of drug sensitivity measurements and tens of thou-
sands of alterations. On such datasets UNCOVER identifies several statistically significant
associations between target values and mutually exclusive alterations in genes sets, with an
enrichment in well-known cancer genes and in known cancer pathways.
Materials and methods
This section describes the problem we study and the algorithms we designed to solve it, that
are implemented in our tool UNCOVER. We also describe the data and computational envi-
ronment for our experimental evaluation.
Algorithms to discover alterations with complementary functional association in cancer
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UNCOVER: Functional complementarity of alterations discovery
The workflow of our algorithm UNCOVER is presented in Fig 2. UNCOVER takes in input
information regarding 1. the alterations measured in a number of samples (e.g., patients or cell
lines), and 2. the value of the target measure for each patient. UNCOVER then identifies the
set of mutually exclusive alterations with the highest association to the target, and employs a
permutation test to assess the significance of the association. Details regarding the computa-
tional problem and the algorithms used by UNCOVER are described in the following sections.
The implementation of UNCOVER is available at https://github.com/VandinLab/UNCOVER.
Computational problem. Let J = {j1, . . ., jm} be the set of samples and let G = {g1, . . ., gn}
be the set of genes for which we have measured alterations in J. We are also given a target pro-
file, that is for each sample j 2 J we have a target value wj 2 R which quantitatively measures a
functional phenotype (e.g., pathway activation, drug response, etc.). For each sample j 2 J we
also have information on whether each g 2 G is altered or not in j. Let Ag be the set of patients
in which gene g 2 G is mutated. We say that a patient j 2 J is covered by gene g 2 G if j 2 Ag i.e.
if gene g is mutated in sample j. Given a set of genes S� G, we say that sample j 2 J is covered
by S if j 2 [g 2 S Ag.
The goal is to identify a set S of at most k genes, corresponding to k subsets S1, S2, . . .Sk
where for each subset Si we have that Si� J, such that the sum of the weights of the elements
covered by S is maximized. We also penalize overlaps between sets when an element is covered
more than once by S by assigning a penalty pj for each of the additional times j is covered by S.
As penalty we use the positive average of the normalized target values if the original weight of
the element was positive. If the original weight of the element was negative we assign a penalty
equal to its weight.
Let cS(j) be the number of sets in S1, . . ., Sk that cover element j 2 J. Therefore for a set S of
genes, we define its weight W(S) as:
WðSÞ ¼
X
j2[s2SAs
wj  
X
j2[s2SAs
ðcSðjÞ   1Þpj
Fig 2. UNCOVER: Functional complementarity of alterations discovery. UNCOVER takes in input the alterations information
and a target profile for a set of samples, and identifies the set of complementary alterations with the highest association to the target
by solving the Target Associated k-Set problem and performing a permutation test.
https://doi.org/10.1371/journal.pcbi.1006802.g002
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The target associated k-set problem. Given a set J of samples, sets Ag1 ; . . . ;Agn describing
alterations of genes G = {g1, . . ., gn} in the set J, weights wj and penalties pj> 0 for each sample
j 2 J find the S of� k elements maximizing W(S).
The following result defines the computational hardness of the problem above.
Theorem 1. The Target Associated k-Set problem is NP-hard.
Proof. The proof is by reduction from the Maximum Weight Submatrix Problem (MWSP)
defined and proved to be NP-hard in [34]. The MSWP takes as input an m × n binary matrix
A and an integer k> 0 and requires to find the m × k column sub-matrix M^ of A that maxi-
mizes the objective function |Γ(M)| − ω(M), where Γ(M) is the set of rows with at least one 1
in columns of M and ω(M) = ∑g 2 M|Γ({g})| − |Γ(M)|.
Given an instance of Maximum Weight Submatrix Problem, we define an instance of the
Target Associated k-Set as follow: the set of samples J corresponds to the rows of A, the set of
genes G corresponds to the columns of A, and the set Sg of samples covered by gene g 2 G is
the subset of the rows in which g has a 1. By setting wj = 1 and pj = 1 for all j 2 J, we have that
the objective function of MWSP corresponds to the weight W(S) for the Target Associated k-
Set therefore the optimal solution of the Target Associated k-Set corresponds to the optimal
solution of MWSP.
ILP formulation. In this subsection we provide an ILP formulation for the Target Associ-
ated k-Set problem. Let xi be a binary variable equal to 1 if set i 2 G is selected and xi = 0 other-
wise. Let zj be a binary variable equal to 1 if element j is covered and zj = 0 otherwise. Let yj
denote the number of sets in the solution covering element j. Finally, let wj be the weight of ele-
ment j and pj be the penalty for element j
In our ILP formulation, the following constraints need to be satisfied by a valid solution:
• the total number of sets in the solution is at most k: ∑i xi� k
• for each element j 2 J we have: yj ¼
P
i:j2Si
xi
• for each element j 2 J, if j is covered by the current solution then the number of times j is
covered in the solution is at least 1: yj� zj
• for each element j 2 J, if j is covered by at least one element in the current solution then j is
covered: zj� yj/k.
With the variables defined above, the score for a given solution is
zðqÞ ¼ max
Xm
j¼1
ðwj þ pjÞzj  
Xm
j¼1
pjyj: ð1Þ
z(q) constitutes the objective function of our ILP formulation.
Greedy algorithm. Since solving ILPs can be impractical for very large datasets, we also
design a k-stage greedy algorithm to solve the Target Associated k-Set problem. During each
stage the algorithm picks 1 set Ai to be part of the solution; this is done by first computing
the total weight of each subset which is defined as the sum of the weights of its elements
WðAiÞ ¼
P
j2Ai
wj. Then the algorithm finds the subset Ai of maximum positive weight and
adds it to the solution. It may be that at some stage ℓ no additional set of positive weight can be
selected, in this case, the solution obtained after stage ℓ − 1 will be our output. At the end of
the iteration the weight of every element j that belonged to the chosen set Ai is set to the nega-
tive of penalty pj, in order to penalize future selections of the same elements. The greedy algo-
rithm is described in Algorithm 1.
Algorithms to discover alterations with complementary functional association in cancer
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Algorithm 1: GREEDY Coverage
Input: A set of elements J (samples), a class I of subsets of J
(genetic alterations) and an integer k (maximum number of alterations
in the solution). Each element j 2 J has an associated weight wj (tar-
get profile) and a penalty pj.
Output: k subsets S1, S2, . . .Sk, where each subset selected is a member
of I, such that the sum of the weights of the elements in the selected
sets is maximized and the overlap between selected sets is minimized.
for ℓ  1 to k do
for i  1 to n do WðAiÞ  
P
j2Ai
wj;
S‘  arg maxWðAiÞ>0fWðAiÞg;
for j 2 Sℓ do wj  −pj;
end
return S1. . .Sk;
We note that our greedy algorithm is analogous to the greedy algorithm for the Maximum
k-Coverage problem [35] with the difference that rather than eliminating the elements already
selected we change their weight to a penalty. Also, assuming it is acceptable to return less
than k sets, we only pick a set if it has a positive weight. The running time of the algorithm is
O(kmn) where m = number of samples and n = number of alterations.
While the greedy algorithm may not return the optimal solution, we prove that it provides
guarantees on the weight of the solution it provides.
Proposition 1. Let S� the optimal solution of the Target Associated k-Set and S^ be the solution
returned by the greedy algorithm. Then WðS^Þ �WðS�Þ=k.
Proof. Note that the weight of subsets in the optimal solution W(S�) can only be lower com-
pared to the original weight of the subsets, since the only weight update operation performed
is to substitute positive weights of elements selected with a negative penalty.
The first subset S^1 selected by our algorithm is the set of maximum weight out of all subsets
and therefore WðS^1Þ �WðS�‘Þ for ℓ = 1. . .k. By the pigeonhole principle, one of these subsets
in the optimal solution must cover at least W(S�)/k worth of elements. Thus
WðS^1Þ �WðS�Þ=k. Therefore the first subset selected by the algorithm already gives a 1/k
approximation of the optimal solution. In subsequent iterations of the algorithm we only pick
additional sets if they have a positive weight so our approximation ratio can only improve.
We also prove that the bound above is tight.
Proposition 2. There are instances of the Target Associated k-Set such that WðS^Þ ¼WðS�Þ=k.
The proof is in S1 Appendix.
While the proposition above is based on an extreme example, our experimental analysis
shows that in practice the greedy algorithm works well and often identifies the optimal solu-
tion. We therefore analyze the greedy algorithm under a generative model in which there is a
set H of k genes with mutually exclusive alterations associated with the target, while each gene
g 2 G \ H is mutated in sample j with probability pg independently of all other events. We also
assume that the weights wj are such that ∑j 2 J wj = 0 and for each j: |wj� 1|. (In practice this is
achieved by normalizing the target values before running the algorithm, by subtracting to each
wj the average value ∑j 2 J wj/m and then dividing the result by the maximum of the absolute
values of the transformed wj’s). Note that this last condition implies that |pj|�1 for all j. We
also assume that for genes in H the following assumptions hold:
• the set H has an association with the target, i.e.: E½WðHÞ� � mc0 for a constant c
0 � 1.
• each gene of H contributes to the weight of H, i.e. for each S�H and each g 2 H \ S we have
E½WðS [ fggÞ�   E½WðSÞ� � WðHÞ
kc00
for a constant c@� 1.
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The following shows that, if enough samples from the generative model are considered, the
greedy algorithm finds the set H associated with the target with high probability.
Proposition 3. If m 2 O(k2 ln(n/δ)) samples from the generative model above are provided to
the greedy algorithm, then the solution of the greedy algorithm is H with probability� δ.
The proof is in S1 Appendix.
Statistical significance. To assess the significance of the solution reported by our algo-
rithms we use a permutation test in which the dependencies among alterations in various
genes are maintained, while the association of alterations and the target is removed. In particu-
lar, a permuted dataset under the null distribution is obtained as follows: the sets Ag ; g 2 G
are the same as observed in the data; the values of the target are randomly permuted across the
samples.
To estimate the p-value for the solutions obtained by our methods we used the following
standard procedure: 1) we run an algorithm (ILP or greedy) on the real dataD, obtaining a
solution with objective function oD; 2) we generate N permuted datasets as described above; 3)
we run the same algorithm on each permuted dataset; 4) the p-value is then given by (e + 1)/
(N + 1), where e is the number of permuted datasets in which our algorithm found a solution
with objective function� oD.
Data and computational environment
Alteration data. We downloaded data for the Cancer Cell Line Encyclopedia on 25th Sep-
tember, 2017 from http://www.broadinstitute.org/ccle. In particular we used the mutation
(single nucleotide variants) and copy number aberrations (CNAs) which are derived from the
original Cancer Cell Line Encyclopedia (CCLE) mutations and CNA datasets. The file we used
is CCLE_MUT_CNA_AMP_DEL_0.70_2fold.MC.gct. It consists of a binary (0/1) matrix
across 1,030 samples and 48,270 gene alterations in the form of mutations, amplifications and
deletions, with a 1 meaning that the alteration is present in a sample, and a 0 otherwise. For
the GDSC experiments [36, 37], we used the alteration provided at https://depmap.org/portal/
download/all/. We downloaded the data on July 6th 2018. In particular we used mutation data
from portal-mutation-2018-06-21.csv that includes binary entries for 18652
mutations. Additionally we considered 22746 amplifications and 22746 deletions computed
from the gene copy number data in portal-copy_number_relative-2018-06-
21.csv, with an amplification defined by a copy number above 2 and a deletion defined by a
copy number below -1.
Target data. In terms of target values we use the same datasets used by [33] to compare
the performance of UNCOVER with REVEALER. In particular we used the following files
available through the Supplementary Material of [33]: CTNBB1_transcriptional
_reporter.gct, which consists of measurements of a β-catenin reporter in 81 cell lines;
NFE2L2_activation_profile.gct, which includes NFE2L2 enrichment profiles for
182 lung cell lines; MEK_inhibitor_profile.gct, which contains MEK-inhibitor PD-
0325901 sensitivity profile in 493 cancer cell lines from the Broad Novartis CCLE14l; and
KRAS_essentiality_profile.gct, which corresponds to the feature KRAS from a
subset of 100 cell lines from the Achilles project dataset. In all these cases we considered the
same direction of association (positive or negative) between alterations and the target as in
[33]. Since our algorithm is very efficient we then decided to run it on a large dataset on
genetic dependencies from Project Achilles (https://portals.broadinstitute.org/achilles), that
uses genome-scale RNAi and CRISPR-Cas9 perturbations to silence or knockout individual
genes. In particular, we use the whole 2.4.2 Achilles dataset (Achilles_QC_v2.4.3.
rnai.Gs.gct) available from the project website. This dataset provides phenotype values
Algorithms to discover alterations with complementary functional association in cancer
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for 5711 targets, corresponding to genes silenced by shRNA. The phenotype values correspond
to ATARiS [38] gene (target) level scores, quantifying the cell viability when the target gene is
silenced by shRNA. These scores are provided for 216 cell lines [19], with 205 of them appear-
ing in CCLE. We also used UNCOVER to analyze a large datasets from the Genomics of Drug
Sensitivity in Cancer (GDSC) project (https://www.cancerrxgene.org/) which provides drug
sensitivity data generated from high-throughput screening using fluorescence-based cell via-
bility assays following 72 hours of drug treatment. In particular, we considered the area
under the curve for each experiment as target. These scores are provided in the file portal-
GDSC_AUC-2018-06-21.txt, available trough the DepMap portal (https://depmap.org)
[39] for 265 compounds and 743 cell lines, with 736 having alteration data in DepMap.
Data preprocessing. To be consistent with REVEALER we discarded features with high
or low frequency, in particular features present in less than 3 samples or more than 50 samples
were excluded from our analyses. The only exception was the MEK-inhibitor example, where
the high frequency threshold was changed to be 100 since the number of original samples was
substantially higher (i.e., 493) for this case. From the Achilles dataset we excluded targets that
have at least one missing value, in particular in this case we exclude 21 of the 5711 sets of target
scores. From the GDSC dataset, since many samples have at least one target with a missing
value, for every target we excluded samples with missing value for that target, that results in a
different number of samples for each target. The number of samples varied between 240 and
705. We filtered alterations to only have alterations with frequencies between 0.1 and 0.25,
removing in this way genes that have high alteration frequency due to genomic features not
important for to the disease (e.g., gene length) [9]. In all our experiments we normalized the
target values before running the algorithm, by subtracting to each weight wj the average value
∑j 2 J wj/m and dividing the result by the standard deviation of the (original) wj’s, in order to
have both positive and negative target values.
Simulated data. We investigated how effective UNCOVER is at finding selected alter-
ations in a controlled setting, where the ground truth is known. We generated target values
according to a normal distribution with mean 0 and standard deviation 1. We tested dataset
with 200, 600, 1000 and 10000 samples. For each dataset we considered the 38002 gene alter-
ations present in CCLE and for each of them we placed alterations in the samples indepen-
dently of all other events with the same frequencies as they appear in CCLE. To be consistent
with the preprocessing done on real data we filtered alterations to only have alterations with
frequencies between 0.1 and 0.25. We also generated a set T of 5 features to have an association
with the target values. This association was varied throughout the experiments to cover differ-
ent percentages of positive and negative targets. In particular we generated the selected features
to cover 100%, 80%, 60%, 40% of the positive target values and 5%, 10%, 15%, 20% of the nega-
tive target values respectively, choosing random subsets of samples with positive or negative
target values. We will refer to the parameter indicating the percentage of samples with positive
target values selected as P and to the parameter for the percentage of samples with negative tar-
get values selected as N. We divided the number of targets covered by each of the 5 mutations
equally.
Computing environment and solver configuration. To describe and solve an ILP we
used AMPL 20150516 and CPLEX 12.6.3. All parameters in CPLEX were left at their default
values. We implemented our greedy algorithm in Python 3.6.1. We run our experiments on
the same datasets considered by REVEALER [33] and on the Achilles project dataset on a Mac-
Book Air with 1.7 GHz Intel Core i7 processor, 8 GB RAM and 500 GB of local storage. Exper-
iments on simulated data were conducted on local nodes of a computing cluster. Each node
had the following configuration: four 2.27 GHz CPUs, 5.71 GB RAM and 241 GB of storage.
Experiments on the GDSC dataset for UNCOVER and REVEALER were conducted on an
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iMac with 3.4 GHz Intel Core i5 processor and 16 GB RAM. For the time comparison between
UNCOVER and REVEALER we run the R code provided in [33] on the same machine used
for UNCOVER, using R 3.5.1. All the parameters were left at their given values except for the
number of permutations used to calculate their p-value, which we changed in order to com-
pare the running time of the methods excluding the time needed to compute p-values.
Results and discussion
We tested UNCOVER on a number of cancer datasets in order to compare its results to the
ones obtained without using the target, to state-of-the-art algorithms, and to test whether
UNCOVER allows the analysis of large datasets. In particular, we first assessed the impact
of the target values on the results of UNCOVER. We then compared UNCOVER with
REVEALER using four datasets described in [33] as well as the GDSC project dataset described
above. We then used simulated data to asses the performance of UNCOVERin finding groups
of alterations associated with a target. We then performed a scalability test using a large dataset
from the Achilles project and alterations from the Cancer Cell Line Encyclopedia (CCLE).
Finally, we used UNCOVER to analyze a drug sensitivity dataset from the GDSC project.
Impact of target
We ran UNCOVER on the GDSC dataset for k = 3 and compared the results obtained when
the target values are not considered in the analysis, obtained running UNCOVER ILP with
k = 3 while setting the target values to 1 for all the samples considered in the analysis of a target
(S1 Table). The latter analysis corresponds to the extraction of sets with high mutual exclusiv-
ity (e.g., by [34]). As expected, the solutions obtained in the two cases are very different: the
solution obtained without considering the target values has one alteration in common with the
solution obtained by UNCOVER using either positive or negative values of the target for only
11 targets of the 265 in the GDSC dataset, and for no target the solutions share more than 1
alteration. An example of the solutions obtained target using UNCOVER and without consid-
ering the target values are shown in Fig 3. We observe that while the solutions obtained consid-
ering the target values display an association with the target profile (positive or negative), the
solution obtained when the target values are not considered, while covering a large set of sam-
ples, does not display any positive or negative association with the target profile. To asses the
association between target values and alterations more consistently we calculated the point
biserial coefficient [40] for all 265 solutions. The coefficient varies between −1 and +1 with 0
implying no correlation. The average value obtained when ignoring the target is −0.02 with
standard deviation 0.05, while the the average value obtained by UNCOVER is 0.20 with stan-
dard deviation 0.05. These results show that a mutual exclusivity analysis that disregards the
values of the target does not identify sets of mutually exclusive alterations associated with tar-
get values. In addition, the genes in solution identified by considering the drug target have a
much more significant enrichment in known cancer genes, as reported in [11], than the genes
in solution identified disregarding the values of the target (p = 3 × 10−12 vs p = 10−2).
Comparison with REVEALER
We run the greedy algorithm and the ILP from UNCOVER on the same four datasets consid-
ered by the REVEALER publication [33]. We used the same values of k used in [33], that is
k = 3 for all the datasets, except from the KRAS dataset where k = 4 was used. For each dataset
we recorded the solution reported by the greedy algorithm, the solution reported by the ILP,
the value of the objective functions for such solutions and the running time to obtain such solu-
tions. For ILP solutions, we also performed the permutation test (see Materials and methods) to
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Fig 3. Impact of the target on the results. UNCOVER results for target Palbociclib considering or ignoring target values. (a)
Solution found by UNCOVER looking for an association with samples with high target values. (b) Solution found by UNCOVER
looking for association with low target values. (c) Solution found by UNCOVER when the target values are ignored. Each panel
shows the value of the target (top row) for various samples (columns), with yellow being negative and blue being positive values. For
each gene in the solution, alterations in each sample are shown in dark blue, while samples not altered are in yellow. The last row
shows the alteration profile of the entire solution.
https://doi.org/10.1371/journal.pcbi.1006802.g003
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compute a p-value using 1000 permutations. The results are reported in Table 1, in which we
also show the results from REVEALER (without initial seeds). Fig 4 shows alteration matrices
and the association with the target for the solutions identified by UNCOVER.
We can see that the greedy algorithm identifies the same solution of the ILP based algo-
rithm in three out of four cases, and that the runtime of the ILP and the runtime of greedy
algorithm are comparable and very low (< 40 seconds) in all cases. In contrast, the running
time of REVEALER is much higher (> 1000 seconds in most cases). (We included all prepro-
cessing in the reported UNCOVER runtimes in Table 1 to ensure a fair comparison with
REVEALER; not including preprocessing our running times are all under 10 seconds). Com-
paring the alteration matrices of the solutions by UNCOVER and the ones of solutions by
REVEALER (S1 Fig) we note that alterations in solutions by UNCOVER tend to have higher
mutual exclusivity and to be more concentrated in high weight samples than alterations in
solutions by REVEALER. As expected, the value of the objective function we use is much
lower for solutions from REVEALER than for solutions from our algorithm.
We then compared the solutions obtained by our algorithms with the solutions from
REVEALER in terms of the information coefficient (IC), that is the target association score
used in [33] as a quality of the solution. Surprisingly, in two out of four datasets UNCOVER,
which does not consider the IC score, identifies solutions with IC score higher (by at least 5%)
than the solutions reported by REVEALER. For the other two cases, in one dataset the IC
Table 1. Comparison of UNCOVER with REVEALER on REVEALER’s datasets.
NFE2L2 activation MEK-inhibitor KRAS essentiality β-catenin activation
UNCOVER(ILP)
solution
KEAP1.MC MUT BRAF.V600E MUT KRAS.G12 13 MUT APC.MC MUT
ATP11B AMP KRAS.G12 13 MUT ZNF385B AMP CTNNB1.MC MUT
SPINT4 DEL NRAS MUT ATP8A2 AMP SLITRK1 AMP
C8orf22 AMP
Objective value 46.17 108.32 28.00 22.97
IC score 0.58 0.49 0.63 0.67
p-value 0.000999 0.000999 0.025974 0.1068931
Running time (s) 14 39 9 9
UNCOVER(Greedy)
solution
KEAP1.MC MUT BRAF MUT KRAS.G12 13 MUT APC.MC MUT
ATP11B AMP KRAS.G12 13 MUT ZNF385B AMP CTNNB1.MC MUT
SPINT4 DEL NRAS MUT ATP8A2 AMP SLITRK1 AMP
C8orf22 AMP
Objective value 46.17 104.29 28.00 22.97
IC score 0.58 0.5 0.63 0.67
Running time (s) 15 35 9 8
REVEALER
solution
KEAP1.MC MUT BRAF MUT KRAS.G12 13 MUT APC.MC MUT
LRP1B DEL KRAS.G12 13 MUT ZNF385B AMP CTNNB1.MC MUT
OR4F13P AMP NRAS MUT LINC00340 DEL ITGBL1 AMP
NUP153 MUT
Objective value 30.35 104.29 21.86 22.12
IC score 0.54 0.5 0.6 0.7
Running time (s) 1615 4965 1243 787
For each of the four targets (NFE2L2 activation, MEK-inhibitor, KRAS essentiality, β-catenin activation) considered in [33], the set of alterations of cardinality k
reported by our ILP algorithm, by our greedy algorithm, and by REVEALER (without seeds) is reported. k is chosen as in [33]. For each pair (algorithm, target) we also
report the (objective) value of our objective function for the solution, the value of the IC score (that is, the objective function used in [33]), and the running time of the
algorithm for the target. For solutions found by our ILP we also report the p-value computed by permutation test using 1000 permutations.
https://doi.org/10.1371/journal.pcbi.1006802.t001
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score is very similar (0.50 vs 0.49) while in the other case the IC score by REVEALER is higher
(0.7 vs 0.67) but the solution reported by REVEALER differs from the solution reported by
UNCOVER by 1 gene only. Interestingly, the latter is the only case where the solution from
the ILP has a p-value> 0.1 (p< 0.03 in all other cases), and therefore the solutions (by our
methods and by REVEALER) for such dataset may be, at least in part, due to random fluctua-
tions of the data.
In terms of biological significance, in most cases the solutions by UNCOVER and by
REVEALER are very similar, with cancer relevant genes identified by both methods. For
NFE2L2 activation, both methods identify KEAP1, a repressor of NFE2L2 activation [41]. For
MEK-inhibitor, both methods find BRAF, KRAS, and NRAS, three well known oncogenic
activators of the MAPK signaling pathway, which contains MEK as well. For KRAS essential-
ity, both methods report mutations in KRAS in the solution. For β-catenin activation, both
methods identify CTNNB1 mutations and APC mutations, that is known to be associated to
β-catenin activation [42]. These results show that UNCOVER identifies relevant biological
solutions that are better than the ones identified by REVEALER when evaluated using our
objective function and also when evaluated according to the objective function of REVEALER
with a running time that is on average two orders of magnitude smaller than required by
REVEALER. Since UNCOVER and REVEALER consider two different objective functions,
it is unclear whether the improvement in running time comes from differences in implementa-
tion choices or from a inherently different computational complexity. However, since
UNCOVER’s objective function is easier to compute than REVEALER’s objective function,
we believe that the use of our objective function plays an important role in the efficiency of
UNCOVER.
Fig 4. Results of UNCOVER on four cancer datasets from [33]. (a) Solution found by ILP and greedy for KRAS essentiality target.
(b) Solution found by ILP and greedy for β-catenin activation target. (c) Solution found by ILP for MEK inhibitor target. (d) Solution
found by greedy for MEK inhibitor target. (e) Solution found by ILP and greedy for NFE2L2 activation target. Each panel shows the
value of the target (top row) for various samples (columns), with yellow being negative and blue being positive values. For each gene
in the solution, alterations in each sample are shown in dark blue, while samples not altered are in yellow. The last row shows the
alteration profile of the entire solution.
https://doi.org/10.1371/journal.pcbi.1006802.g004
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We also compared the solutions obtained by UNCOVER and by REVEALER on the GDSC
dataset (S2 Table). For both algorithms we obtained the solutions for k = 3. For UNCOVER,
we considered the solution returned by the ILP. For REVEALER, we could only obtain solu-
tions for 246 targets, since for the other targets REVEALER terminated with an error message.
Due to the high running time of REVEALER, we only obtained sets of alterations associated
with positive values of the target (Table 2). For 33 targets the solution by UNCOVER and the
solution by REVEALER share 1 alteration, while for 33 targets the solution by UNCOVER and
the solution by REVEALER share 2 alterations; for no target UNCOVER and REVEALER
report the same solution. This shows that the two methods identify completely different solu-
tion in most (> 73%) of the cases. We compared the solutions obtained by UNCOVER and
by REVEALER using the IC score considered by REVEALER but not from UNCOVER: sur-
prisingly, in more than 50% of the cases (113 out of 208) the IC score of the solution from
UNCOVER is higher than the IC of the solution from REVEALER. On the other hand, for
all targets the solution by REVEALER is worst than the solution by UNCOVER when the
UNCOVER objective function is considered. We also compared UNCOVER and REVEALER
evaluating the association between target values and alterations in the solutions using a mea-
sure of association that is not considered by the two algorithms. In particular, we considered
the point biserial correlation coefficient [40]. In more than 95% of the cases (199 out of 208)
the point biserial correlation coefficient between the solution from UNCOVER and the
target is higher than the point biserial correlation coefficient between the solution from
REVEALER and the target, that is, the solution from UNCOVER has an higher association
with the target than the solution from REVEALER. On average, the solution from UNCOVER
has a point biserial correlation coefficient that is 37% higher than the point biserial correlation
coefficient of the solution from REVEALER. Moreover, the average effect size of solutions
from UNCOVER is more than 80% higher than the average effct size of solutions from
REVEALER (Table 2). In addition, the genes in solutions from UNCOVER have a much
higher enrichment (p = 3 × 10−13; 7-fold enrichment) for known cancer genes than solutions
from REVEALER (p = 2 × 10−4; 3-fold enrichment). Analogously, more KEGG pathways
display a significant enrichment in genes from UNCOVER solutions than from REVEALER
solutions (22 vs 11). We also compared the running time of the two methods: UNCOVER
required 3 hours to complete the analysis, while REVEALER required 9 days. Overall, these
results show that UNCOVER obtains better results than REVEALER not only in terms of the
UNCOVER objective function but also in terms of the score from REVEALER as well as in
terms of a independent measure of association, while being 70 times faster than REVEALER.
Results on simulated data
For each combination we generated 10 simulated datasets as described in Materials and meth-
ods. Each dataset contains a planted set of 5 alterations associated with the target. We used
both the greedy algorithm and the ILP from UNCOVER with k = 5 to attempt to find the 5
Table 2. Comparison of UNCOVER with REVEALER on GDSC dataset.
Number of genes Avg. effect size Cancer genes enrichment
p-value (fold enrich.)
Enriched KEGG pathways
REVEALER 570 0.11 2 × 10−4 (3) 11
UNCOVER 491 0.20 3 × 10−12 (7) 22
For each algorithm we report the distinct number of genes in its solutions, the average effect size of the algorithm’s solutions, the p-value and fold enrichment for known
cancer genes, and the number of KEGG pathways enriched for genes in the solutions by the algorithm.
https://doi.org/10.1371/journal.pcbi.1006802.t002
Algorithms to discover alterations with complementary functional association in cancer
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1006802 May 23, 2019 14 / 24
correct alteration, and evaluated our algorithms both in terms of fraction of the correct (i.e.,
planted) solution reported and running time.
As shown in Fig 5, the greedy algorithm is faster than the ILP for all datasets, and the differ-
ence in running time increases as the number m of samples increases, with the runtime of the
greedy algorithm being almost two orders of magnitude smaller than the runtime of the ILP
for m = 1000 samples. In addition, for a fixed number of samples and alterations, the running
time of the greedy algorithm is constant, that is it does not depend on the properties of the
planted solution, while the running time of the ILP varies greatly depending on these parame-
ters. For m = 10, 000 samples the running time of the ILP becomes extremely high, so we
restricted to consider only two sets of parameters (p − n = 0.95 and p − n = 0.2). In this case the
ILP took between 44 minutes and 7 hours to complete, while the greedy algorithm terminates
in 5 minutes.
In terms of the quality of the solutions found, as expected the ILP outperforms the greedy
(Fig 6) but the difference among the two tends to disappear when the number of samples
is higher. In addition, since the ILP finds the optimal solution, we can see that for a limited
number of samples we may not reliably identify the planted solution with 200 samples unless
the planted solution appears almost only in positive targets and in almost all of them (p −
n = 0.95), while for m = 1000 we can reliably identify the planted solution using both the ILP
and the greedy algorithm even when the association with the target is weaker (p − n = 0.6).
When m = 10, 000, both the ILP and the greedy algorithm perform well in terms of the quality
Fig 5. Running time of UNCOVER on simulated data. The running time (expectation and standard deviation) of the greedy
algorithm and of the ILP approach are shown for different number of samples and the difference p − n between the fraction p of
samples with positive target and the fraction n of samples with negative target covered by the the correct solution.
https://doi.org/10.1371/journal.pcbi.1006802.g005
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of the solution: the ILP finds the correct alterations on every experiment and the greedy identi-
fies the whole planted solution in all experiments but one for p − n = 0.2, for which it still
reports a solution containing 4 out of 5 genes in the planted solution.
These results show that for a large number of samples the greedy algorithm reliably identi-
fies sets of alterations associated with the target, as predicted by our theoretical analysis, and is
much faster than the ILP. For smaller sample size the ILP identifies better solutions than the
greedy and has a reasonable running time.
Analysis of Achilles project data
The efficiency of UNCOVER renders the analysis of a large number of targets, such as the
ones available through the Achilles project, possible. After preprocessing the dataset included
5690 functional phenotypes as targets, and for each of these the CCLE provides alteration
information for 205 samples and 31137 alterations. In total we have therefore run 11380
instances (i.e., 5690 targets screened for positive and for negative associations) looking for
both positive and negative association with target values. Since the number of samples (205) is
relatively small, we have run only the ILP from UNCOVER on the whole Achilles dataset and
looked for solutions with k = 3 genes. The runtime of UNCOVER to find both positive and
negative associations, including preprocessing, is 24 hours. Based on the runtime required on
Fig 6. Quality of solutions of UNCOVER on simulated data. The fraction of genes in the planted (i.e., correct) solution found by
the greedy algorithm and by the ILP approach are shown for different number of samples and the difference p − n between the
fraction p of samples with positive target and the fraction n of samples with negative target covered by the the correct solution.
https://doi.org/10.1371/journal.pcbi.1006802.g006
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the instances reported in [33] (see the Section Comparison with REVEALER), running
REVEALER on this dataset would have required about 5 months of compute time.
To identify statistically significant associations with targets in the Achilles project dataset
we used a nested permutation test. We first run the permutation test with 10 permutations on
all instances (i.e., on all targets for both positive association and negative association). We then
considered all the instances with the lowest p-value (1/11) and performed a permutation test
with 100 permutations only for such instances. We the iterated such procedure once more,
selecting all the instances with lowest p-value (1/101) and performing a permutation test with
1000 permutations only for such instances. For positive association we found 60 solutions with
p-value< 0.001, and for negative association we found 102 solutions with p-value< 0.001.
The solutions with p-value < 0.001 (with 1000 permutations) are reported in S3 Table. See S2
Fig for some corresponding alteration matrices.
The genes in the solutions by UNCOVER with p-value 1/1001 are enriched (p = 2 × 10−12
by Fisher exact test; 8 fold enrichment) for well-known cancer genes. We also tested whether
genes in solutions by UNCOVER (with p-value 1/1001) are enriched for interactions, by com-
paring the number of interactions in iRefIndex [43] among genes in such solution with the
number of interactions in random sets of genes of the same cardinality. Genes in solutions by
UNCOVER are significantly enriched in interactions (p = 7 × 10−3 by permutation test; 2 fold
enrichment). In addition, the genes in solutions by UNCOVER are also enriched in genes in
well-known pathways: 12 KEGG pathways [44] have a significant (corrected p� 0.05) overlap
with genes in solutions by UNCOVER and four of these (endometrial cancer, glioma, hepato-
cellular carcinoma, EGFR tyrosine kinase inhibitor resistance) are cancer related pathways. In
addition, the targets (i.e., genes) with solutions of p-value 1/1001 are enriched (p = 5 × 10−4 by
permutation test; 6 fold enrichment) for interactions in iRefIndex and for well-known can-
cer genes (p = 2 × 10−12 by Fisher exact test; 8 fold enrichment) as reported in [11]. These
results show that UNCOVER enables the identification of groups of well known cancer genes
with significant associations to important targets in large datasets of functional target profiles.
For example, for target (i.e., silenced gene) TSG101, related to cell growth, UNCOVER identi-
fies the gene set shown in Fig 7 as associated to reduced cell viability. ERBB2 is a well known
cancer gene and CDH4 is frequently mutated in several cancer types, and both are associated
to cell growth.
Fig 7. Solution by UNCOVER for silencing of TSG101 (data from Achilles project). The alteration matrix of genes in the solution
identified by UNCOVER as associated to reduced cell viability is reported. The value of the target (top row) for various samples
(columns) is shown, with yellow being negative and blue being positive values. For each gene in the solution, alterations in each
sample are shown in dark blue, while samples not altered are in yellow. The last row shows the alteration profile of the entire
solution.
https://doi.org/10.1371/journal.pcbi.1006802.g007
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Analysis of GDSC project data
We use UNCOVER to analyze the GDSC project data, identifying sets of alterations associated
with drug sensitivity. After preprocessing, the dataset included 64144 alterations and 265 tar-
gets, and for each of these the number of cell lines with available data varied between 240 and
705. In total we have therefore run 530 instances (i.e., 265 targets screened for positive and for
negative associations) looking for both positive and negative association with target values.
We used the UNCOVER ILP for all instances to obtain solutions with k = 3 genes. For each
solution, we use 100 permutations to compute its p-value. For positive association we found 51
solutions with p-value < 0.01, and for negative association we found 41 solutions with p-value
< 0.01. We used the following procedure to focus on the most significant solutions: we run
UNCOVER with k = 4 and computed the p-values for the solutions using 100 permutations;
we then identified targets whose solution for k = 3 have p-value< 0.01 and are contained in
the solution for the same target with k = 4 and have p-value p< 0.01 for k = 4. In total, this pro-
cedure identifies 23 solutions for positive association and 22 solutions for negative associa-
tions. These solutions are reported in S4 Table.
The genes in the solutions identified as above are enriched (p = 9 × 10−10 by Fisher exact
test; 20 fold enrichment) for well-known cancer genes, as reported in [11]. We also tested
whether these genes in solutions are enriched for interactions, by comparing the number of
interactions in iRefIndex [43] among genes in such solution with the number of interac-
tions in random sets of genes of the same cardinality. Genes in solutions by UNCOVER are
significantly enriched in interactions (p = 2 × 10−2 by permutation test; 6 fold enrichment). In
addition, these genes are also enriched in genes in well-known pathways: 21 KEGG pathways
[44] have a significant (corrected p� 0.05) overlap with genes in solutions by UNCOVER and
19 of these are cancer related pathways (e.g., ErbB signaling pathway) or related to drug resis-
tance (e.g., EGFR tyrosine kinase inhibitor resistance).
For Palbociclib, UNCOVER identifies RB1 mutations, GRB7 amplifications, and RB1 dele-
tions with significant association with reduced sensitivity to drug. RB1 is a well known cancer
gene. The alterations are shown in Fig 3a. While RB1 mutations and RB1 deletions are signifi-
cantly associated when considered in isolation (the association of single alterations with drug
sensitivity and the drug targets have been obtained from https://www.cancerrxgene.org/),
GRB7 amplification is not associated with the target values when considered in isolation.
GRB7 encodes a growth factor receptor-binding protein that interacts with epidermal growth
factor receptor (EGFR). Both RB1 and EGFR are related to the cell cycle pathway, that is the
pathway target of the compound, and the drug targets (CDK4, CDK6) as well EGFR are mem-
bers of the PI3K-AKT pathway. For Sunitinib, UNCOVER identifies mutations in SETD2,
ARHGAP19, and RB1, with significant association with reduced sensitivity to drug. The alter-
ations are shown in Fig 8a. RB1 is a well known cancer gene and SETD2 has tumor suppressor
functionality. None of these alterations have significant association with drug sensitivity when
considered in isolations. RB1 and SETD2 are involved in protein localization to chromatin,
and ARHGAP19 is part of Rho mediated remodeling. For PLX-4720-2, UNCOVER identifies
mutations in BRAF, CD244, and ARSB with significant association to increased sensitivity to
drug. The alterations are shown in Fig 8b. BRAF is a well-known cancer gene; it is the target of
the compound and BRAF mutations have significant association to increased sensitivity to the
compound, while the other two alterations do not. BRAF and CD244 are part of natural killer
cell mediated cytotoxicity pathway, while ARSB is involved in the regulation of cell adhesion,
cell migration and invasion in colonic epithelium [45], and is also part of metabolism related
pathways. For VX-11e, UNCOVER identifies mutations in BRAF, KRAS, and NRAS, with sig-
nificant association to increased sensitivity to drug. The alterations are shown in Fig 8c. Only
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Fig 8. Solution by UNCOVER on GDSC drug sensitivity data data. The alteration matrix of genes in some solutions identified by
UNCOVER as associated to drug sensitivity for different targets. (a) Solution for reduced sensitivity to Sunitinib. (b) Solution for
increased sensitivity to PLX-4720-2. (c) Solution for increased sensitivity to VX-11e. Each panel shows the value of the target (top
row) for various samples (columns), with yellow being negative and blue being positive values. For each gene in the solution,
alterations in each sample are shown in dark blue, while samples not altered are in yellow. The last row shows the alteration profile of
the entire solution.
https://doi.org/10.1371/journal.pcbi.1006802.g008
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BRAF mutations have significant association with the target when considered in isolation. The
pathway target for the compound is the ERK MAPK signaling pathway, to which all three
alterations are related. All three genes have well identified roles in cancer. These results show
that UNCOVER enables the identification of groups of relevant genes, many related to cancer,
with significant associations to important targets in large datasets of drug sensitivity profiles.
Conclusion
In this work we study the problem of identifying sets of mutually exclusive alterations associ-
ated with a quantitative target profile.
We provide a combinatorial formulation for the problem, proving that the corresponding
computational problem is NP-hard. We design two efficient algorithms, a greedy algorithm
and an ILP-based algorithm, for the identification of sets of mutually exclusive alterations asso-
ciated with a target profile. We provide a formal analysis for our greedy algorithm, proving
that it returns solutions with rigorous guarantees in the worst-case as well under a reasonable
generative model for the data. We implemented our algorithms in our method UNCOVER,
and showed that it finds sets of alterations with a significant association with target profiles in
a variety of scenarios. By comparing the results of UNCOVER with the results of REVEALER
on four target profiles used in the REVEALER publication [33] and on a large dataset from the
GDSC project, we show that UNCOVER identifies better solutions than REVEALER, even
when evaluated using REVEALER objective function. Moreover, UNCOVER is much faster
than REVEALER, allowing the analysis of large datasets such as the dataset from project Achil-
les and from the GDSC project, in which UNCOVER identifies a number of associations
between functional target profiles and gene set alterations.
Our tool UNCOVER (as well as REVEALER) relies on the assumption that the mutual
exclusivity among alterations is due to functional complementarity. Another explanation for
mutual exclusivity is the fact that each cancer may comprise different subtypes, with different
subtypes being characterized by different alterations [27]. UNCOVER can be used to identify
sets of mutually exclusive alterations associated with a specific subtype whenever the subtype
information is available, by assigning high weight to samples of the subtype of interest and low
weight to samples of the other subtypes. In addition, while we consider a penalty based on
mutual exclusivity, other types of penalties may be used to identify sets of alterations associated
with a target profile. The study of the theoretical properties of the problem and the analysis of
the results with different penalties are interesting directions of future research.
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S1 Fig. Results of UNCOVER and REVEALER on four cancer datasets from [33]. (a) Solu-
tion found by ILP and greedy for KRAS essentiality target. (b) Solution found by ILP and
greedy for β-catenin activation target. (c) Solution found by ILP for MEK inhibitor target. (d)
Solution found by greedy for MEK inhibitor target. (e) Solution found by ILP and greedy for
NFE2L2 activation target. The value of the target (top row) for various samples (columns) is
shown, with yellow being negative and blue being positive values. For each gene in the solu-
tion, alterations in each sample are shown in dark blue, while samples not altered are in yellow.
The last row shows the alteration profile of the entire solution.
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S2 Fig. Alteration matrices for some results of UNCOVER the Achilles project data. The
alteration matrix of genes in some solutions identified by UNCOVER as associated to
increased cell viability for different targets. (a) ACSL3 (b) HNRNPH3 (c) MAP3K1 (d)
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S1 Appendix. Supplementary text. Proofs of Proposition 2 and of Proposition 3.
(PDF)
S1 Table. Solutions found by UNCOVER on the GDSC dataset when the target values are
ignored. The table reports the solutions each target, the objective function value, and the point
biserial correlation coefficient.
(XLSX)
S2 Table. Solutions found by UNCOVER and by REVEALER on the GDSC dataset. The
table reports the solutions associated to positive values of the target. For each target and algo-
rithm we report the solution, the objective function value, the IC score, the point biserial corre-
lation coefficient and its p-value. The number of alterations shared by UNCOVER’s solution
and REVEALER’s solutions are shown as well.
(XLSX)
S3 Table. Solutions found by UNCOVER on the Achilles dataset. The table reports the solu-
tions associated to negative values of the target and the solutions associated to positive values
of the target. In both cases only solutions with the lowest p-value are reported. For each target
we report the objective function value for the optimal solution, the set of alterations of cardi-
nality 3 and the p-value computed by permutation test using 1000 permutations.
(XLSX)
S4 Table. Solutions found by UNCOVER on the GDSC dataset. The table reports the solu-
tions associated to negative values of the target and the solutions associated to positive values
of the target. In both cases only solutions filtered using the procedure described in Section
“Analysis of GDSC project data”.
(XLSX)
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